AEGIR-INSIGHTS
Aegir Insights, a leading provider of decision-making software, data, and intelligence for the offshore wind sector, has raised €8.5M in Series A funding, led by Seaya Andromeda with the participation of Climentum Capital. The company will use the funds to develop the next generation of its web platform, encompassing decision software, data, and intelligence products for the offshore wind industry.
Offshore wind power is among the fastest growing segments within clean energy investments according to the International Renewable Energy Agency (IRENA)’s latest World Energy Transition Outlook (2023), indicating the necessity of offshore wind to grow from today’s 64 GW capacity to 494 GW by 2030 and reach 2,465 GW by 2050.1 However, the project development process remains long and complex, taking as long as 10 years from site identification to commercial operations.
Aegir Insights’ solutions play a crucial role in making data-driven decisions, optimizing development, and reducing costs, thereby accelerating investment in the sector. This is critical in the current environment of cost volatility to ensure optimal capital allocation and project economics. Aegir Insights’ existing client base includes leading developers such as BP, Equinor, and JERA, and it is expanding further into governmental and financial services segments.
The €8.5M in Series A funding will support the development of Aegir Insights’ software-as-a-service (SaaS) platform, data, and intelligence offerings. The company’s technology roadmap includes solutions for simulating price-competitive auctions, streamlined project and portfolio analysis, and broadening functionality to evaluate hybrid assets and system integration. The funding will also enable Aegir Insights to expand its expert client support, serving as a trusted independent advisor.
Aegir Insights was founded in 2020 by CEO Scott Urquhart and CCO Rikke Nørgaard, who, between them, have almost 35 years of energy industry experience working for major renewable energy players, including Ørsted and Vattenfall.
Scott Urquhart, co-founder and CEO of Aegir Insights, said: “We are excited to have found investors with such strong experience in scaling SaaS businesses in the energy sector.” Commenting further on the unique value proposition provided by Seaya Andromeda and Climentum Capital, he said, “Their hands-on experience and renewable sector network will help us accelerate our product roadmap, where we are aiming to set the market standard for offshore wind decision software.”
Rikke Nørgaard, co-founder and CCO of Aegir Insights, added: “Over the past three years, we’ve built a unique product offering, serving offshore wind developers, investors, and governments around the world. This is an important milestone in our journey, both for Aegir Insights as a company and for our clients, that will enable us to enhance our products and mission to accelerate offshore wind deployment.”
Pablo Pedrejon Garcia, Partner at Seaya Andromeda said: “At Seaya Andromeda, we are very excited to partner with Scott and Rikke on the next phase of Aegir’s growth. They have developed a unique solution that is poised to change how investment and planning are done in the offshore wind sector. Under their leadership and considering the huge opportunity within this vertical, we are convinced that Aegir Insights will become the ‘gold standard’ solution for offshore wind decision-making.”
Morten Halborg, Managing Partner at Climentum Capital stated: “In a crowded field of cleantech solutions, Aegir Insights brings clarity with a data-driven software solution. Aegir tackles real-world challenges in the offshore wind industry, offering an integrated platform that will restore profitability while significantly reducing CO2 emissions. Aegir's focus on logic and impact perfectly aligns with our mission to invest in companies that substantially contribute to our CO2 emissions reduction target of 1 million tons annually at fund close.”
Link to press images: https://we.tl/t-aTIeMrlt1E
About Aegir Insights
Smarter, faster, greener.
Aegir Insights is a technology-driven company offering decision-making software, data, and intelligence products for the offshore wind sector. Aegir Insights serves a global client base across corporate, financial, and governmental segments, with product coverage across more than 60 offshore wind markets.
Aegir Insights leverages data science and deep industry experience to help global renewable players make smarter decisions. Its expertise lies in contextualizing complex information through the use of proprietary models developed in close cooperation with industry and academia. Going beyond data, Aegir Insights brings independent strategic insights based on industry experience.
About Seaya Andromeda
Seaya Andromeda is the largest ClimateTech Venture Capital in Southern Europe. With €300M assets under management, Andromeda is an SFDR Article 9 fund on a mission to address global sustainability challenges and deliver profits with purpose through investments in technology-driven companies focusing on Energy & Decarbonisation, the Circular Economy, and the Sustainable Food Value Chain.
Seaya Andromeda is a fund of Seaya – the leading European and Latin American Venture Capital platform, with offices in Madrid, Barcelona, and Mexico City, that invests in exceptional entrepreneurs who are building global technology companies. Seaya raised its first funding in 2013 and currently manages over €700M across five early-stage venture funds. Seaya accelerates the growth of startups by leveraging the founder’s strategic vision, providing them with Seaya’s global platform, its extensive network of founders, investors and multinational corporations, as well as all its experience in the global expansion of companies such as Glovo, Cabify, Wallbox (NYSE:WBX), Spotahome, Clarity AI, Clicars, Alma, and RatedPower.
https://seaya.vc/seaya-andromeda
About Climentum Capital
Climentum Capital is a Venture Capital firm based in Copenhagen, Berlin, and Stockholm. The team invests in European hard-tech startups that cut emissions at the core of industries. The pioneering Article 9 fund has a double incentives structure, with carry indexed on both CO2 emissions reductions and financial returns.
The General Partners Malin Carlström, Dörte Hirschberg, Morten Halborg, and Stefan Mård target late Seed and Series A investments in the five sectors that demonstrate the largest CO2 reduction potential: Energy, Industry, Food, and Agriculture, Buildings, and Transportation. Climentum’s portfolio includes Continuum, Qvantum Industries, Jolt Technologies, Novatron, one.five, and more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213625041/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Approximately 7% of people in the United States (U.S.) have atopic dermatitis – a common, chronic, and flaring inflammatory skin disease, characterized by persistent itch and recurrent skin lesions1-4 While currently available treatments may improve some signs and symptoms of the disease, many patients do not respond optimally to approved therapies and do not experience itch relief and clear skin to the same degree2,5-7 Nemluvio® (nemolizumab) is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and epidermal dysregulation in atopic dermatitis2,9-11 This approval follows Nemluvio’s recent approval for the treatment of adults with prurigo nodularis from the U.S. Food and Drug Administration earlier in August 202412 Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug
Andersen Global forstærker sin dækning af Asien-Stillehavsregionen med ejendomsrådgivere i Australien13.12.2024 19:39:00 CET | Pressemeddelelse
Andersen Global styrker sin platform i Asien og Stillehavsregionen gennem en samarbejdsaftale med Charter Keck Cramer, der er et af Australiens førende, uafhængige ejendomsrådgivningsfirmaer. Det, der i 1970 begyndte som en lille virksomhed, Charter Keck Cramer, har siden udviklet sig til et tværfagligt firma med mere end 170 eksperter, der er fordelt på fem kontorer i Australien og Singapore. Firmaet tilbyder et omfattende udvalg af ejendomsrelaterede ydelser, herunder værdiansættelser inden for bolig- og erhvervsejendomme, ejendoms- og udviklingsrådgivning, ejendomsdata og analyser samt strategisk planlægning og byøkonomi samt kvantitetsopmåling. Charter Keck Cramer betjener en mangfoldig australsk og international kundebase, herunder offentlige og private virksomheder, ejere og udviklere, større banker og finansielle institutioner, institutionelle ejere og truster, statslige organer og familiekontorer. "Vores vækst over de seneste 54 år er drevet af vores uafhængige, skræddersyede t
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press release
Businesses Must Employ a Multi-Layered Approach to Fight GenAI Fraud Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unli
Capcom Announces Onimusha Way of the Sword, Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom